Mesenchymal stem cells, disease treatment agents and microparticles
Patent Information
- Application Number
- JP2018043227
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2018-03-09
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2038-03-09
AI Technical Summary
【0010】 本発明によると、免疫性疾患及び肝疾患の新規治療剤を提供することができる。
Smart Images

Figure 0007593580000001 
Figure 0007593580000002 
Figure 0007593580000003
Abstract
Description
[Technical field]
[0001] The present invention relates to mesenchymal stem cells, therapeutic agents, and microparticles. [Background technology]
[0002] Heart transplants are performed to treat end-stage heart failure, coronary artery disease (CAD), arrhythmia, hypertrophic cardiomyopathy, and congenital heart disease. Similarly, hematopoietic stem cells are used to treat blood cancers (leukemia, lymphoma, myeloma) and blood diseases such as primary immunodeficiency, aplastic anemia, and myelodysplasia, kidneys are used to treat end-stage renal failure, livers are used to treat cholestatic diseases such as cirrhosis, fulminant hepatic necrosis, hepatocellular carcinoma, biliary atresia and metabolic diseases in children, and non-stasis diseases such as primary sclerosing cholangitis and autoimmune hepatitis, lungs are used for patients with respiratory depression or respiratory failure, pancreatic islets or islet cells are used for diabetic patients, and small intestines are used for patients with intestinal disorders such as gastroschisis, Hirschsprung's disease, and autoimmune enteritis, intestinal resections due to mesenteric thromboembolism, extensive Crohn's disease, and malabsorption. Other transplants include skin allografts, cartilage transplants, bone transplants, corneal transplants, and fetal thymus transplants. Rejection is a major complication following transplantation of these organs, etc. In particular, hyperacute rejection occurs within 48 hours after transplantation due to existing complement-fixing antibodies against graft antigens. Since there is no effective treatment for this condition other than graft removal, the development of a new treatment is desired.
[0003] On the other hand, autoimmune hepatitis is known as an immune disease. This autoimmune hepatitis has both acute and chronic clinical symptoms, but it is an autoimmune disease that occurs when immunological tolerance to one's own liver cells breaks down due to some mechanism. The involvement of preceding infections and drugs has also been suggested as a trigger for the onset of the disease. The number of autoimmune hepatitis patients in Japan is about 20,000, of which chronic autoimmune hepatitis accounts for about 1.8% of chronic hepatitis cases. About 30% of deaths due to autoimmune hepatitis occur within six months of diagnosis, and treatment for acute liver failure at the time of diagnosis is considered important for improving the prognosis (see Non-Patent Document 1). In addition, in chronic autoimmune hepatitis, liver regeneration and connective tissue are repeated due to chronic inflammation, resulting in an increase in extracellular matrix mainly composed of collagen (liver fibrosis), which progresses to liver cirrhosis. When cirrhosis progresses from the compensated stage, where no symptoms appear, to the decompensated stage, which is accompanied by advanced fibrosis, it is currently not possible to adequately treat the condition with existing drugs and treatments. Therefore, there is a need for the development of new therapeutic drugs with a different mechanism of action from conventional drugs.
[0004] Mesenchymal stem cells are multipotent precursor cells that were first isolated from bone marrow by Friedenstein (1982) (see Non-Patent Document 2). It has been revealed that mesenchymal stem cells exist in various tissues such as bone marrow, umbilical cord, and fat, and mesenchymal stem cell transplantation is expected to be a new treatment method for various intractable diseases (see Patent Documents 1 and 2). Recently, it has been found that cells with equivalent functions exist in the interstitial cells of fetal appendages such as adipose tissue, placenta, umbilical cord, and fetal membrane. Therefore, mesenchymal stem cells are sometimes called mesenchymal stromal cells. [Prior art documents] [Patent documents]
[0005] [Patent Document 1] JP 2012-157263 A [Patent Document 2] Special Publication No. 2012-508733 [Non-patent literature]
[0006] [Non-Patent Document 1] Hepatologist Textbook, pp.205-208, Nankodo Co., Ltd., published March 30, 2013 [Non-Patent Document 2] Pittenger FMet. al., Science 284,pp.143-147(1999) Summary of the Invention [Problem to be solved by the invention]
[0007] In the above-mentioned circumstances, an object of the present invention is to provide a novel therapeutic agent and a novel therapeutic method for immune diseases and liver diseases.
[0008] As a result of intensive research to solve the above problems, the present inventors have discovered that mesenchymal stem (stromal) cells (MSCs) highly expressing one or more microRNAs selected from the group consisting of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p, and miR-634, and microparticles derived from mesenchymal stem cells highly expressing one or more microRNAs selected from the group consisting of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p, and miR-634, are effective in treating immune diseases and liver diseases, thereby completing the present invention. According to the present invention, it is possible to provide a therapeutic agent effective for treating immune diseases and liver diseases.
[0009] [1] Mesenchymal stem cells characterized by high expression of one or more microRNAs selected from the group consisting of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634. [2] The mesenchymal stem cell described in [1], wherein the microRNA is contained in microparticles derived from mesenchymal stem cells. [3] The mesenchymal stem cell according to [2], wherein the microparticles are exosomes. [4] A mesenchymal stem cell according to any one of [1] to [3], which is of allogeneic origin. [5] A mesenchymal stem cell according to any one of [1] to [4], which is derived from adipose tissue. [6] A disease therapeutic agent comprising the mesenchymal stem cells and / or their culture supernatant according to any one of [1] to [5]. [7] A disease therapeutic agent comprising microparticles derived from mesenchymal stem cells described in any one of [1] to [5]. [8] The disease therapeutic agent according to [6] or [7], wherein the disease is an immune disease or a liver disease. [9] Microparticles characterized by high expression of one or more microRNAs selected from the group consisting of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634. Effect of the Invention
[0010] According to the present invention, a novel therapeutic agent for immune diseases and liver diseases can be provided. [Brief description of the drawings]
[0011] [Figure 1] FIG. 2 is a diagram showing the expression of each microRNA in the mesenchymal stem cell-derived microparticles of the present invention in comparison with conventional mesenchymal stem cell-derived microparticles. [Diagram 2] FIG. 1 shows the therapeutic effect of the mesenchymal stem cells of the present invention on autoimmune hepatitis model mice (AST). [Diagram 3] FIG. 1 shows the therapeutic effect of the mesenchymal stem cells of the present invention on a mouse model of autoimmune hepatitis (ALT). [Figure 4] FIG. 2 is a graph showing the therapeutic effect of the microparticles of the present invention on a mouse model of autoimmune hepatitis (AST). [Diagram 5] FIG. 1 shows the therapeutic effect of the microparticles of the present invention on a mouse model of autoimmune hepatitis (ALT). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0012] The mesenchymal stem cells, microparticles, and disease therapeutic agent of the present invention will be described in detail below.
[0013] [Mesenchymal stem cells] The mesenchymal stem cells of the present invention are characterized by high expression of one or more microRNAs selected from the group consisting of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634.
[0014] MicroRNA (miRNA) is a non-coding RNA gene that is approximately 22 bases long and does not code for proteins. Each miRNA induces expression suppression in complementary or partially complementary messenger RNA, and one type of miRNA is involved in the expression control of multiple genes. The gene expression regulation mechanism related to this miRNA is said to be related to various life phenomena, life functions, diseases, etc. (See Experimental Medicine Special Edition: A Complete Guide to Real-Time PCR Experiments that Makes Sense from the Principles, etc.).
[0015] In the present invention, high expression of microRNA means that the expression level of the microRNA is higher than that of cells obtained under conventional culture conditions, preferably 1.5 times or more, more preferably 2 times or more, and even more preferably 3 times or more. Here, conventional culture conditions include, for example, culture in a DMEM medium containing 10% FBS.
[0016] Compared to conventional mesenchymal stem cells, the mesenchymal stem cells of the present invention need only highly express one or more microRNAs selected from the group consisting of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634, and preferably highly express two or more, more preferably three or more, even more preferably four or more, particularly preferably five or more, more particularly preferably six or more, and most preferably all of these microRNAs. Specifically, the mesenchymal stem cells of the present invention express one or more microRNAs selected from the group consisting of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634 at a level of 1.5 times or more, more preferably 2 times or more, and even more preferably 3 times or more, compared to mesenchymal stem cells obtained under conventional culture conditions (e.g., culture in DMEM medium containing 10% FBS).
[0017] The mesenchymal stem cells of the present invention contain the microRNA in intracellular microparticles. The microparticles are vesicles that are produced in mesenchymal stem cells and released from the mesenchymal stem cells and have a size that can be confirmed by electron microscopy. The size of the microparticles is an average particle diameter of about 1 nm to 1,000 nm, preferably 10 nm to 500 nm, and more preferably 30 nm to 200 nm. Here, the average particle diameter is the average value of the diameter of each particle measured by dynamic light scattering or electron microscopy. The microparticles can have a lipid bilayer surrounding a biomolecule. In addition, examples of the microparticles include membrane particles, membrane vesicles, microvesicles, nanovesicles, microvesicles (average particle diameter 30 to 1,000 nm), exosome-like vesicles, exosomes (average particle diameter 30 to 200 nm), ectosome-like vesicles, ectosomes, exovesicles, and the like, and preferably exosomes. Microparticles derived from different types of mesenchymal stem cells can also be distinguished based on their intracellular origin, density, shape, sedimentation rate, lipid composition, protein markers, and mode of secretion (i.e., after a signal (inducible) or spontaneous (constitutive)) in sucrose. For example, the microparticles are fractionated to 1.0 to 1.5 g / mL, preferably 1.1 to 1.3 g / mL, by density gradient centrifugation. Furthermore, the microparticles contain any of phosphatidylserine, cholesterol, sphingomyelin, and ceramide as their constituent lipids.
[0018] The microparticles contain proteins, fatty acids, other nucleic acids, and the like in addition to microRNA.
[0019] Examples of the above proteins and fatty acids include IL-10, HGF (Hepatocyte Growth Factor), Apolipoprotein A-2, Pigment epithelium-derived factor (PEDF), SERPINF1, haptoglobin, pelargonic acid, lauric acid, myristic acid, pentadecanoic acid, isopentadecanoic acid, palmitic acid, isopalmitic acid, margaric acid, isoheptadecanoic acid, stearic acid, isostearic acid, oleic acid, elaidic acid, linoleic acid, nonadecylic acid, isononadecylic acid, arachidic acid, 11Z-eicosenoic acid, Dihomo-γ-linolenic acid, arachidonic acid, erucic acid, 13Z, 16Z-Docosadienoic acid, 13Z, 16Z,19Z-Docosadienoic acid, adrenic acid, and Clupanodonic acid. acid, preferably IL-10, HGF, apolipoprotein A-2, pigment epithelium-derived factor (PEDF), SERPINF1, haptoglobin, pelargonic acid, lauric acid, myristic acid, pentadecanoic acid, isopentadecanoic acid, palmitic acid, isopalmitic acid, margaric acid, isoheptadecanoic acid, stearic acid, isostearic acid, oleic acid, elaidic acid, linoleic acid, arachidic acid, 11Z-eicosenoic acid, arachidonic acid, erucic acid, 13Z, 16Z-docosadienoic acid, and the like. factor (PEDF), SERPINF1), haptoglobin, myristic acid, pentadecanoic acid, palmitic acid, margaric acid, isoheptadecanoic acid, stearic acid, oleic acid, linoleic acid, nonadecylic acid, erucic acid, 13Z,Examples of the microparticles containing the above-mentioned acids include 13Z, 16Z-Docosadienoic acid, and particularly preferably IL-10, HGF, palmitic acid, margaric acid, stearic acid, oleic acid, and 13Z, 16Z-Docosadienoic acid.
[0020] In the present invention, mesenchymal stem cells refer to cells that have the ability to differentiate into one or more types of cells belonging to the mesenchymal system (such as bone cells, cardiac muscle cells, chondrocytes, tendon cells, and adipocytes), preferably two or more cells, and more preferably three or more cells, and can proliferate while maintaining the ability. The term mesenchymal stem cells used in the present invention refers to the same cells as stromal cells, and does not particularly distinguish between the two. They may also be simply referred to as mesenchymal cells. Examples of tissues that contain mesenchymal stem cells include adipose tissue, umbilical cord, bone marrow, umbilical cord blood, endometrium, placenta, amnion, chorion, decidua, dermis, skeletal muscle, periosteum, dental follicle, periodontal ligament, dental pulp, and tooth germ. For example, adipose tissue-derived mesenchymal stem cells refer to mesenchymal stem cells contained in adipose tissue, and may also be referred to as adipose tissue-derived stromal cells. Of these, from the standpoint of effectiveness in treating immune diseases and liver diseases, ease of availability, and the like, adipose tissue-derived mesenchymal stem cells, umbilical cord-derived mesenchymal stem cells, bone marrow-derived mesenchymal stem cells, placenta-derived mesenchymal stem cells, and dental pulp-derived mesenchymal stem cells are preferred, adipose tissue-derived mesenchymal stem cells and umbilical cord-derived mesenchymal stem cells are more preferred, and adipose tissue-derived mesenchymal stem cells are most preferred.
[0021] The mesenchymal stem cells in the present invention may be derived from the same species as the subject (specimen) to be treated, or may be derived from a different species. The species of mesenchymal stem cells in the present invention include humans, horses, cows, sheep, pigs, dogs, cats, rabbits, mice, and rats, and are preferably derived from the same species as the subject (specimen) to be treated. The mesenchymal stem cells in the present invention may be derived from the subject (specimen) to be treated, i.e., autologous cells, or may be derived from another subject of the same species, i.e., allogeneic cells. Allogeneic cells are preferred.
[0022] Since mesenchymal stem cells are unlikely to cause rejection even in allogeneic subjects, donor cells prepared in advance can be expanded and cryopreserved and used as the mesenchymal stem cells in the disease treatment agent of the present invention. Therefore, compared with the case of preparing and using autologous mesenchymal stem cells, from the viewpoints of ease of commercialization and ease of obtaining a stable and consistent effect, it is more preferable that the mesenchymal stem cells in the present invention are allogeneic.
[0023] In the present invention, mesenchymal stem cells refer to any cell population containing mesenchymal stem cells, in which at least 20%, preferably 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 93%, 96%, 97%, 98% or 99% are mesenchymal stem cells.
[0024] In the present invention, adipose tissue means tissue containing adipocytes and stromal cells including microvascular cells, and is, for example, tissue obtained by surgically excising or aspirating subcutaneous fat of a mammal. Adipose tissue can be obtained from subcutaneous fat. It is preferable to obtain it from the same animal as the subject of administration of adipose tissue-derived mesenchymal stem cells described later, and considering administration to humans, it is more preferable to obtain it from human subcutaneous fat. The individual that supplies the subcutaneous fat may be alive or dead, but the adipose tissue used in the present invention is preferably tissue collected from a living individual. When collecting from an individual, liposuction can be exemplified by, for example, PAL (power-assisted) liposuction, Erchonia laser liposuction, or body jet liposuction, and it is preferable not to use ultrasound from the viewpoint of maintaining the state of the cells.
[0025] In the present invention, the umbilical cord is a white tubular tissue that connects the fetus and the placenta, and is composed of the umbilical vein, umbilical artery, gelatinous tissue (Wharton's jelly), umbilical cord matrix itself, etc., and contains a large amount of mesenchymal stem cells. The umbilical cord is preferably obtained from an animal of the same species as the subject (administration subject) who will use the disease therapeutic agent of the present invention, and when considering administration of the disease therapeutic agent of the present invention to humans, a human umbilical cord is more preferable.
[0026] In the present invention, bone marrow refers to the soft tissue that fills the cavity of bone and is a hematopoietic organ. Bone marrow contains bone marrow fluid, and cells present therein are called bone marrow cells. Bone marrow cells include red blood cells, granulocytes, megakaryocytes, lymphocytes, adipocytes, mesenchymal stem cells, hematopoietic stem cells, vascular endothelial precursor cells, etc. Bone marrow cells can be collected, for example, from human iliac bone, long bone, or other bones.
[0027] In the present invention, the term "mesenchymal stem cells derived from each tissue, such as adipose tissue-derived mesenchymal stem cells, umbilical cord-derived mesenchymal stem cells, and bone marrow-derived mesenchymal stem cells" refers to any cell population containing mesenchymal stem cells derived from each tissue, such as adipose tissue-derived mesenchymal stem cells, umbilical cord-derived mesenchymal stem cells, and bone marrow-derived mesenchymal stem cells. At least 20%, preferably 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 93%, 96%, 97%, 98% or 99% of the cell population are mesenchymal stem cells derived from each tissue, such as adipose tissue-derived mesenchymal stem cells, umbilical cord-derived mesenchymal stem cells, and bone marrow-derived mesenchymal stem cells.
[0028] The mesenchymal stem cells of the present invention highly express one or more genes selected from the group consisting of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p, and miR-634, and also have, for example, characteristics that are characteristic of the mesenchymal stem cells, such as growth characteristics (e.g., population doubling ability from passage to senescence, doubling time), karyotype analysis (e.g., normal karyotype, maternal lineage or neonatal lineage), and flow cytometry (e.g., FACS analysis). The cells may be characterized by surface marker expression, immunohistochemistry and / or immunocytochemistry (e.g., epitope detection), gene expression profiling (e.g., gene chip arrays; polymerase chain reaction such as reverse transcription PCR, real-time PCR, conventional PCR, etc.), miRNA expression profiling, protein arrays, protein secretion such as cytokines (e.g., plasma clotting analysis, ELISA, cytokine arrays), metabolites (metabolomic analysis), and other methods known in the art.
[0029] (Method for preparing mesenchymal stem cells and mesenchymal stem cell-derived microparticles) The method for preparing mesenchymal stem cells and mesenchymal stem cell-derived microparticles that highly express one or more genes selected from the group consisting of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634 is not particularly limited, and they can be prepared, for example, as follows. That is, mesenchymal stem cells are isolated and cultured from tissues such as adipose tissue, umbilical cord, bone marrow, etc. according to methods known to those skilled in the art, and cells and microparticles that highly express one or more selected from the group consisting of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p, and miR-634 are isolated using a cell sorter, magnetic beads, ultracentrifugation, reagents, etc., using an antibody that specifically binds to any of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p, and miR-634, and obtained. In addition, by inducing the expression of one or more microRNAs selected from the group consisting of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634 in mesenchymal stem cells by culturing them using a specific medium, it is also possible to obtain mesenchymal stem cells and mesenchymal stem cell-derived microparticles in which one or more microRNAs selected from the group consisting of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634 are highly expressed.In the cell population and microparticles obtained by this induction, it is preferable that 50% or more of the cell population and microparticles highly express one or more microRNAs selected from the group consisting of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5, miR-129-2-3p, miR-129-1-3p and miR-634, and 70% or more of the cell population and microparticles highly express one or more microRNAs selected from the group consisting of miR- It is more preferable that one or more microRNAs selected from the group consisting of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634 are highly expressed, and 80% or more of the microRNAs selected from the group consisting of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195 It is further preferred that one or more microRNAs selected from the group consisting of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634 are highly expressed, and 90% or more of the microRNAs selected from the group consisting of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634 are highly expressed. It is particularly preferred that one or more microRNAs selected from the group consisting of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634 are highly expressed, and it is most preferred that the cell population and microparticles are substantially homogeneous in which one or more microRNAs selected from the group consisting of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634 are highly expressed. The following is a detailed description of a method for preparing mesenchymal stem cells and microparticles in which one or more microRNAs selected from the group consisting of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634 are highly expressed.
[0030] Mesenchymal stem cells can be prepared by methods well known to those skilled in the art. As an example, a method for preparing adipose tissue-derived mesenchymal stem cells is described below. Adipose tissue-derived mesenchymal stem cells may be obtained by the production method described in U.S. Pat. No. 6,777,231, for example, and can be produced by a method including the following steps (i) to (iii): (i) obtaining a cell suspension by enzymatic digestion of adipose tissue; (ii) sedimenting the cells and resuspending the cells in an appropriate medium; and (iii) culturing the cells on a solid surface and removing cells that do not exhibit binding to the solid surface.
[0031] The adipose tissue used in step (i) is preferably washed. Washing can be performed by vigorous agitation and sedimentation using a physiologically compatible saline solution (e.g., phosphate buffered saline (PBS)). This is to remove contaminants contained in the adipose tissue (also called debris, e.g., damaged tissue, blood, red blood cells, etc.) from the tissue. Therefore, washing and sedimentation are generally repeated until the debris is totally removed from the supernatant. Since the remaining cells exist as clumps of various sizes, it is preferable to treat the washed cell clumps with an enzyme (e.g., collagenase, dispase, trypsin, etc.) that weakens or destroys intercellular bonds in order to dissociate the cells while minimizing damage to the cells themselves. The amount and duration of such enzymes vary depending on the conditions used and are known in the art. Instead of or in combination with such enzyme treatment, the cell clumps can be decomposed by other treatment methods such as mechanical agitation, ultrasonic energy, and heat energy, but it is preferable to perform only enzyme treatment in order to minimize damage to the cells. When an enzyme is used, it is desirable to inactivate the enzyme using a medium or the like after an appropriate period of time in order to minimize harmful effects on cells.
[0032] The cell suspension obtained by step (i) contains a slurry or suspension of aggregated cells as well as various contaminating cells, such as red blood cells, smooth muscle cells, endothelial cells, and fibroblasts. The aggregated cells and the contaminating cells may then be separated and removed, but this step may be omitted since they can be removed by adhesion and washing in step (iii) described below. The separation and removal of the contaminating cells may be achieved by centrifugation, which forcibly separates the cells into a supernatant and a precipitate. The resulting precipitate containing the contaminating cells is suspended in a physiologically compatible solvent. The suspended cells may contain red blood cells, but the lysis step is not necessarily required since the red blood cells are excluded by selection by adhesion to a solid surface, as described below. Methods known in the art can be used to selectively lyse red blood cells, such as lysis with ammonium chloride followed by incubation in a hypertonic or hypotonic medium. After lysis, the lysate may be separated from the desired cells, for example by filtration, centrifugation, or density fractionation.
[0033] In step (ii), the cells in suspension may be washed once or multiple times, centrifuged, and resuspended in culture medium to increase the purity of the mesenchymal stem cells. Alternatively, the cells may be separated based on cell surface marker profiles or based on cell size and granularity.
[0034] The medium used for resuspension is not particularly limited as long as it is a medium capable of culturing mesenchymal stem cells, but such a medium may be prepared by adding serum to a basal medium and / or adding one or more serum substitutes such as albumin, transferrin, fatty acids, insulin, sodium selenite, cholesterol, collagen precursors, trace elements, 2-mercaptoethanol, 3'-thiolglycerol, etc. These media may further contain substances such as lipids, amino acids, proteins, polysaccharides, vitamins, growth factors, low molecular weight compounds, antibiotics, antioxidants, pyruvic acid, buffers, inorganic salts, etc., as necessary.
[0035] Examples of the basal medium include IMDM medium, Medium 199 medium, Eagle's Minimum Essential Medium (EMEM) medium, αMEM medium, Dulbecco's modified Eagle's Medium (DMEM) medium, Ham's F12 medium, RPMI 1640 medium, Fischer's medium, MCDB201 medium, and mixed media thereof.
[0036] Examples of the serum include, but are not limited to, human serum, fetal bovine serum (FBS), bovine serum, calf serum, goat serum, horse serum, porcine serum, sheep serum, rabbit serum, rat serum, etc. When serum is used, it may be added to the basal medium at 5 v / v% to 15 v / v%, preferably 10 v / v%.
[0037] Examples of the fatty acid include, but are not limited to, linoleic acid, oleic acid, linoleic acid, arachidonic acid, myristic acid, palmitoyl acid, palmitic acid, and stearic acid. Examples of the lipid include, but are not limited to, phosphatidylserine, phosphatidylethanolamine, and phosphatidylcholine. Examples of the amino acid include, but are not limited to, L-alanine, L-arginine, L-aspartic acid, L-asparagine, L-cysteine, L-cystine, L-glutamic acid, L-glutamine, and L-glycine. Examples of the protein include, but are not limited to, ecotin, reduced glutathione, fibronectin, and β2-microglobulin. Examples of the polysaccharide include, but are not limited to, glycosaminoglycans, and among glycosaminoglycans, hyaluronic acid, heparan sulfate, and the like. Examples of growth factors include, but are not limited to, platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF), transforming growth factor beta (TGF-β), hepatocyte growth factor (HGF), epidermal growth factor (EGF), connective tissue growth factor (CTGF), vascular endothelial growth factor (VEGF), etc. From the viewpoint of using the adipose-derived mesenchymal stem cells obtained in the present invention for cell transplantation, it is preferable to use a xeno-free medium that does not contain xenogeneic components such as serum. Such a medium is provided as a medium prepared in advance for mesenchymal stem cells (stromal cells) by, for example, PromoCell, Lonza, Biological Industries, Veritas, R&D Systems, Corning, Rohto, etc.
[0038] Next, in step (iii), the cells in the cell suspension obtained in step (ii) are cultured on a solid surface without differentiation, using the appropriate cell culture medium described above, at an appropriate cell density and culture conditions. In the present invention, the term "solid surface" refers to any material that allows the binding and adhesion of the adipose tissue-derived mesenchymal stem cells of the present invention. In a specific embodiment, such a material is a plastic material that has been treated to promote the binding and adhesion of mammalian cells to its surface. The shape of the culture vessel having a solid surface is not particularly limited, but a petri dish, a flask, or the like is preferably used. To remove unbound cells and cell debris, the cells are washed after incubation.
[0039] In the present invention, cells that ultimately remain bound and adhered to the solid surface can be selected as a cell population of adipose tissue-derived mesenchymal stem cells.
[0040] The selected cells may be analyzed for surface antigens by conventional methods such as flow cytometry to confirm that they are adipose tissue-derived mesenchymal stem cells of the present invention. Furthermore, they may be examined for their ability to differentiate into each cell lineage, and such differentiation may be performed by conventional methods.
[0041] The mesenchymal stem cells of the present invention can be prepared as described above, but may also be defined as cells having the following characteristics: (1) When cultured in standard medium, it exhibits adhesion to plastic. (2) surface antigens CD44, CD73, and CD90 are positive, and CD31 and CD45 are negative; and (3) They can be differentiated into bone cells, adipocytes, and chondrocytes under appropriate culture conditions.
[0042] From the mesenchymal stem cells obtained by the above step (iii), cells highly expressing miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634 can be obtained by selectively isolating them using immunological techniques such as a cell sorter or magnetic beads. In addition, by culturing in a specific medium capable of inducing the expression of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634, it is possible to induce the expression of each miRNA in mesenchymal stem cells and efficiently obtain mesenchymal stem cells and mesenchymal stem cell-derived microparticles with high expression of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634. Furthermore, by culturing the mesenchymal stem cells obtained by the above step (iii) under specific culture conditions such as hypoxic culture, it is possible to induce the expression of each miRNA in the mesenchymal stem cells and efficiently obtain mesenchymal stem cells and mesenchymal stem cell-derived microparticles with high expression of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634. As the condition for the above hypoxic culture, an oxygen concentration of about 0% to 5% is preferable, 0.2% to 3% is more preferable, 0.5% to 2% is even more preferable, and about 1% is particularly preferable.
[0043] The mesenchymal stem cells prepared above are treated with trypsin-EDTA solution, etc., and the resulting cell suspension is centrifuged (room temperature, 400G, 5 minutes) to remove the supernatant. Staining Buffer (1% BSA-PBS) is added to the cells, and 1×10 6Prepare the cell suspension at 100μL / 500μL, pipette the cell suspension to a uniform concentration, and then dispense 50μL into new 1.5mL microtubes. Add the primary antibody (Mouse anti human TFPI, Sekisui diagnostics, ADG4903) at a concentration of 5-20μg / mL to the dispensed cell suspension, suspend the cells, and react for 30 minutes to 1 hour in the dark and refrigerate. Wash three times with 1mL of staining buffer, add staining buffer to make 50uL, add the secondary antibody (Anti Mouse IgG alexar488, Thermofisher Scientific, A21202) at a concentration of 1-10μg / mL, suspend the cells, and react for 30 minutes to 1 hour in the dark and refrigerate. After washing three times with 1 mL of staining buffer, add 300 μL of PI buffer (prepared by adding 28.8 μL of propidium iodide solution (SIGMA, P4864) to 14.4 mL of staining buffer) and suspend well. The cells are then passed through a tube with a cell strainer and separated by fluorescence activated cell sorting (FACS).
[0044] (Mesenchymal stem cell cryopreservation) The mesenchymal stem cells in the present invention may be cells that have been repeatedly frozen and thawed as appropriate, so long as they have a disease treatment effect. In the present invention, cryopreservation can be performed by suspending the mesenchymal stem cells in a cryopreservation solution known to those skilled in the art and cooling them. Suspension can be performed by detaching the cells with a detaching agent such as trypsin, transferring them to a cryopreservation container, treating them appropriately, and then adding the cryopreservation solution.
[0045] The cryopreservation solution may contain DMSO (Dimethyl sulfoxide) as a cryoprotectant, but since DMSO has the property of inducing differentiation of mesenchymal stem cells in addition to cytotoxicity, it is preferable to reduce the DMSO content. Examples of substitutes for DMSO include glycerol, propylene glycol, and polysaccharides. When DMSO is used, it contains 5% to 20%, preferably 5% to 10%, and more preferably 10%. In addition, it may contain additives described in WO2007 / 058308. As such a cryopreservation solution, for example, cryopreservation solutions provided by Bio Verde, Japan Genetics, ReproCell, Zenoac, Cosmo Bio, Kohjin Bio, Thermo Fisher Scientific, etc. may be used.
[0046] When the above-mentioned suspended cells are cryopreserved, they may be stored at a temperature between -80°C and -100°C (for example, -80°C), and any freezer capable of achieving said temperature may be used. Although not particularly limited, in order to avoid abrupt temperature changes, the cooling rate may be appropriately controlled using a programmable freezer. The cooling rate may be appropriately selected depending on the components of the cryopreservation solution, and may be performed according to the manufacturer's instructions for the cryopreservation solution.
[0047] The storage period is not particularly limited as long as the cells cryopreserved under the above conditions retain the same properties as before freezing after thawing, and may be, for example, 1 week or more, 2 weeks or more, 3 weeks or more, 4 weeks or more, 2 months or more, 3 months or more, 4 months or more, 5 months or more, 6 months or more, 1 year or more, or more. Since cell damage can be suppressed by storing at a lower temperature, the cells may be transferred to the gas phase above liquid nitrogen (about -150°C or less to -180°C or less) for storage. When storing in the gas phase above liquid nitrogen, storage containers well known to those skilled in the art can be used. Although not particularly limited, for example, when storing for 2 weeks or more, it is preferable to store in the gas phase above liquid nitrogen.
[0048] The thawed mesenchymal stem cells may be cultured appropriately until the next cryopreservation. The mesenchymal stem cells are cultured using a medium capable of culturing the above-mentioned mesenchymal stem cells, and may be cultured at a culture temperature of about 30 to 40°C, preferably about 37°C, in an atmosphere of CO2-containing air, although this is not particularly limited. The CO2 concentration is about 2 to 5%, preferably about 5%. In the culture, after the cells reach an appropriate confluency for the culture vessel (for example, the cells occupy 50% to 80% of the culture vessel), the cells may be detached with a detaching agent such as trypsin, and seeded at an appropriate cell density in a separately prepared culture vessel to continue the culture. When seeding the cells, a typical cell density is 100 cells / cm. 2 ~100,000 cells / cm 2 , 500 cells / cm 2 ~50,000 cells / cm 2 , 1,000~10,000 cells / cm 2 , 2,000~10,000 cells / cm 2 In a specific embodiment, the cell density is 2,000 to 10,000 cells / cm. 2 It is preferable to adjust the period until the appropriate confluency is reached to 3 to 7 days. During the culture, the medium may be appropriately replaced as necessary.
[0049] Cryopreserved cells can be thawed by methods well known to those skilled in the art, such as by leaving the cells to stand or shake them in a 37°C incubator or water bath.
[0050] The mesenchymal stem cells of the present invention may be in any state, for example, cells recovered by detaching cells during culture, or cells frozen in a cryopreservation solution. The use of cells obtained by the same lot of expansion culture and divided into small portions for cryopreservation is preferable in terms of the same stable action and effect and excellent ease of handling. The mesenchymal stem cells in a cryopreserved state may be thawed immediately before use and directly mixed with a solution such as an infusion or medium while still suspended in the cryopreservation solution. Alternatively, the cryopreservation solution may be removed by a method such as centrifugation and then suspended in a solution such as an infusion or medium. Here, the "infusion" in the present invention refers to a solution used in human treatment, and includes, but is not limited to, physiological saline, Japanese Pharmacopoeia physiological saline solution, 5% glucose solution, Japanese Pharmacopoeia glucose injection solution, Ringer's solution, Japanese Pharmacopoeia Ringer's solution, lactate Ringer's solution, acetate Ringer's solution, solution No. 1 (initiation solution), solution No. 2 (dehydration supply solution), solution No. 3 (maintenance solution), solution No. 4 (postoperative recovery solution), etc.
[0051] [Microparticles derived from mesenchymal stem cells] The mesenchymal stem cell-derived microparticles of the present invention are characterized by high expression of one or more genes selected from the group consisting of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634.
[0052] The mesenchymal stem cell-derived microparticles of the present invention may express one or more genes selected from the group consisting of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634 at a higher level than other microparticles. Specifically, the mesenchymal stem cell-derived microparticles of the present invention may express one or more genes selected from the group consisting of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634 at a higher level than microparticles obtained under conventional culture conditions (e.g., culture in DMEM medium containing 10% FBS). Preferably, the expression is 1.5 times or more, more preferably 2 times or more, and even more preferably 3 times or more, as compared to mesenchymal stem cells obtained under conventional culture conditions. The microparticles derived from mesenchymal stem cells of the present invention may express one or more selected from the group consisting of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p, and miR-634 at a high level, as compared to other microparticles, but preferably express two or more, more preferably three or more, even more preferably four or more, particularly preferably five or more, even more particularly preferably six or more, and most preferably all of these microRNAs at a high level.
[0053] The microparticles of the present invention are microparticles obtained from mesenchymal stem cells and are produced by mesenchymal stem cells. The microparticles derived from mesenchymal stem cells of the present invention may be those contained in mesenchymal stem cells, those contained in mesenchymal stem cell culture supernatant, or those isolated from mesenchymal stem cells or mesenchymal stem cell culture supernatant. That is, the microparticles derived from mesenchymal stem cells of the present invention may be in any form, and may be in the form of mesenchymal stem cells that have the ability to contain or secrete microparticles, as well as the microparticles themselves. Methods for isolating microparticles include ultracentrifugation, microfiltration, capture by antibodies, and the use of microfluidic systems. The isolated microparticles may contain cells such as mesenchymal stem cells, or may contain mesenchymal stem cell culture medium.
[0054] The microparticles derived from mesenchymal stem cells in the present invention can be collected from the culture supernatant obtained by culturing mesenchymal stem cells using the above-mentioned medium. When collecting the culture supernatant, for example, mesenchymal stem cells are made subconfluent or confluent in a culture vessel, and the medium is replaced with a new medium, and the culture is further carried out for 1 to 5 days, and the culture supernatant can be collected. This culture supernatant can be used as the liver disease or immune disease therapeutic agent of the present invention, but the microparticles can also be separated by ultracentrifugation, density gradient centrifugation, various microparticle separation kits, etc., and used as a material for the immune disease therapeutic agent or liver disease therapeutic agent of the present invention. The therapeutic agent for immune diseases and liver diseases of the present invention may contain, in addition to the microparticles, mesenchymal stem cells themselves capable of encapsulating or secreting the microparticles. When the therapeutic agent for immune diseases and liver diseases contains mesenchymal stem cells capable of encapsulating or secreting the microparticles, it can be interpreted that the inclusion of the mesenchymal stem cells simultaneously satisfies the requirement of containing the microparticles.
[0055] A specific explanation of the microparticles derived from mesenchymal stem cells in the present invention can be given by the explanation of the microparticles contained intracellularly in mesenchymal stem cells in the section on mesenchymal stem cells of the present invention described above.
[0056] [Immune disease treatment and liver disease treatment] The therapeutic agent for immune diseases and therapeutic agent for liver diseases of the present invention contain mesenchymal stem (stromal) cells (MSCs) that highly express one or more microRNAs selected from the group consisting of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p, and miR-634 of the present invention described above, or microparticles derived from mesenchymal stem cells that highly express one or more microRNAs selected from the group consisting of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p, and miR-634. The immune disease therapeutic agent and liver disease therapeutic agent of the present invention can improve immune diseases and liver diseases. The explanation of the above section on mesenchymal stem cells and mesenchymal stem cell-derived microparticles contained in the immune disease therapeutic agent and liver disease therapeutic agent of the present invention can be applied.
[0057] The immune disease therapeutic agent and liver disease therapeutic agent of the present invention may contain, in addition to the above-mentioned mesenchymal stem cells or mesenchymal stem cell-derived microparticles, pharma- ceutically acceptable carriers and additives according to the usual method according to the purpose and form of the agent, so long as the effect of the present invention is not impaired. Examples of such carriers and additives include, but are not limited to, isotonicity agents, thickeners, sugars, sugar alcohols, preservatives (preservatives), bactericides or antibacterial agents, pH regulators, stabilizers, chelating agents, oily bases, gel bases, surfactants, suspending agents, binders, excipients, lubricants, disintegrants, foaming agents, fluidizing agents, dispersants, emulsifiers, buffers, solubilizers, antioxidants, sweeteners, sour agents, colorants, flavoring agents, fragrances, or refreshing agents. Representative components include, for example, the following carriers and additives.
[0058] Examples of the carrier include aqueous carriers such as water and aqueous ethanol; examples of the isotonicity agent (inorganic salt) include sodium chloride, potassium chloride, calcium chloride, magnesium chloride, etc.; examples of the polyhydric alcohol include glycerin, propylene glycol, polyethylene glycol, etc.; examples of the thickener include carboxyvinyl polymer, hydroxyethylcellulose, hydroxypropylmethylcellulose, methylcellulose, alginic acid, polyvinyl alcohol (completely or partially saponified), polyvinylpyrrolidone, macrogol, etc.; examples of the sugar include cyclodextrin, glucose, etc.; examples of the sugar alcohol include xylitol, sorbitol, mannitol, etc. (which may be in any of the d-, l- or dl-forms); examples of the preservative, bactericide, or antibacterial agent include dibutylhydroxytoluene, butylhydroxyanisole, alkyldiaminoethylglycine hydrochloride, sodium benzoate, ethanol, benzalkonium chloride, and benzethonium chloride. Examples of the pH adjuster include, for example, chlorhexidine gluconate, chlorobutanol, sorbic acid, potassium sorbate, trometamol, sodium dehydroacetate, methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, butyl parahydroxybenzoate, oxyquinoline sulfate, phenethyl alcohol, benzyl alcohol, biguanide compounds (specifically, polyhexanide hydrochloride (polyhexamethylene biguanide) and the like), Glokil (trade name manufactured by Rhodia), and the like. For example, hydrochloric acid, boric acid, aminoethylsulfonic acid, epsilon-aminocaproic acid, citric acid, acetic acid, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, sodium bicarbonate, sodium carbonate, borax, triethanolamine, monoethanolamine, diisopropanolamine, sulfuric acid, magnesium sulfate, phosphoric acid, polyphosphoric acid, propionic acid, oxalic acid, gluconic acid, fumaric acid, lactic acid, tartaric acid, malic acid, succinic acid, gluconolactone, ammonium acetate, etc.;Examples of stabilizers include dibutylhydroxytoluene, trometamol, sodium formaldehyde sulfoxylate (Rongalit), tocopherol, sodium pyrosulfite, monoethanolamine, aluminum monostearate, glycerin monostearate, sodium hydrogensulfite, sodium sulfite, etc.; examples of oily bases include vegetable oils such as olive oil, corn oil, soybean oil, sesame oil, cottonseed oil, etc., and medium-chain fatty acid triglycerides, etc.; examples of aqueous bases include macrogol 400, etc.; examples of gel bases include carboxyvinyl polymers, gums, etc.; examples of surfactants include polysorbate 80, hydrogenated castor oil, glycerin fatty acid esters, sorbitan sesquioleate, etc.; examples of suspending agents include white beeswax, various surfactants, arabinose, etc. Examples of suitable binders include beer gum, powdered gum arabic, xanthan gum, soybean lecithin, etc.; examples of suitable binders include hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidone, polyvinyl alcohol, etc.; examples of suitable excipients include sucrose, lactose, starch, corn starch, crystalline cellulose, light anhydrous silicic acid, etc.; examples of suitable lubricants include sucrose fatty acid esters, magnesium stearate, talc, etc.; examples of suitable disintegrants include low-substituted hydroxypropyl cellulose, crospovidone, croscarmellose sodium, etc.; examples of suitable foaming agents include sodium bicarbonate, etc.; and examples of suitable fluidizing agents include sodium aluminometasilicate, light anhydrous silicic acid, etc.;
[0059] The immune disease therapeutic agent and liver disease therapeutic agent of the present invention can be provided in various forms, such as solid, semi-solid, and liquid, depending on the purpose. For example, they can be used in the form of solid agents (tablets, powders, powders, granules, capsules, etc.), semi-solid agents [ointments (hard ointments, soft ointments, etc.), creams, etc.], liquid agents [lotions, extracts, suspensions, emulsions, syrups, injections (including infusions, embedded injections, sustained injections, and injections prepared just before use), dialysis agents, aerosols, soft capsules, drinks, etc.], patches, poultices, etc. The immune disease therapeutic agent and liver disease therapeutic agent of the present invention can also be used in the form of a solution or emulsion in an oily or aqueous vehicle. Furthermore, the immune disease therapeutic agent and liver disease therapeutic agent of the present invention can be applied to the affected area by spraying, and can also be used in the form of a gel or sheet at the affected area after spraying. The therapeutic agent for immune diseases and therapeutic agent for liver diseases of the present invention can also be applied to the affected area after forming the above-mentioned mesenchymal stem cells into a sheet-like or three-dimensional structure.
[0060] The therapeutic agent for immune diseases and therapeutic agent for liver diseases of the present invention can be used by suspending or diluting them using infusion fluids such as physiological saline, Japanese Pharmacopoeia physiological saline solution, 5% glucose solution, Japanese Pharmacopoeia glucose injection, Ringer's solution, Japanese Pharmacopoeia Ringer's solution, lactate Ringer's solution, acetate Ringer's solution, bicarbonate Ringer's solution, solution No. 1 (starting solution), solution No. 2 (dehydration rehydration solution), solution No. 3 (maintenance solution), solution No. 4 (postoperative recovery solution), or a cell culture medium such as DMEM, and can be used by suspending or diluting them preferably in physiological saline, 5% glucose solution, solution No. 1 (starting solution), and more preferably in 5% glucose solution, solution No. 1 (starting solution).
[0061] When the immune disease therapeutic agent and liver disease therapeutic agent of the present invention are in the form of a liquid preparation, the pH of the immune disease therapeutic agent and liver disease therapeutic agent is not particularly limited as long as it is within a medicamentously, pharmacologically (pharmaceutical) or physiologically acceptable range, and an example of the pH range is 2.5 to 9.0, preferably 3.0 to 8.5, and more preferably 3.5 to 8.0.
[0062] When the immune disease therapeutic agent and liver disease therapeutic agent of the present invention are liquid preparations, the osmotic pressure of the immune disease therapeutic agent and liver disease therapeutic agent is not particularly limited as long as it is within the range acceptable to the living body. An example of the osmotic pressure ratio of the composition of the present invention is preferably 0.7 to 5.0, more preferably 0.8 to 3.0, and even more preferably 0.9 to 1.4. The osmotic pressure can be adjusted by a method known in the art using inorganic salts, polyhydric alcohols, sugar alcohols, sugars, etc. The osmotic pressure ratio is the ratio of the osmotic pressure of the sample to the osmotic pressure of 286 mOsm (0.9 w / v% sodium chloride aqueous solution) based on the 15th revised Japanese Pharmacopoeia, and the osmotic pressure is measured with reference to the osmotic pressure measurement method (freezing point depression method) described in the Japanese Pharmacopoeia. The standard solution for osmolality ratio measurement (0.9 w / v% sodium chloride aqueous solution) is prepared by drying sodium chloride (Japanese Pharmacopoeia standard reagent) at 500-650°C for 40-50 minutes, allowing it to cool in a desiccator (silica gel), and then accurately weighing out 0.900 g of it and dissolving it in purified water to make exactly 100 mL, or use a commercially available standard solution for osmolality ratio measurement (0.9 w / v% sodium chloride aqueous solution).
[0063] The immune disease therapeutic agent and liver disease therapeutic agent of the present invention can be administered to a subject by oral administration, subcutaneous administration, intramuscular administration, intravenous administration, intraarterial administration, intrathecal administration, intraperitoneal administration, sublingual administration, rectal administration, vaginal administration, intraocular administration, nasal administration, inhalation, transdermal administration, implant, direct administration by spraying onto the surface of an organ, and application of a sheet or the like. From the viewpoint of the efficacy of the immune disease therapeutic agent and liver disease therapeutic agent of the present invention, preferred are implant, administration into the hepatic artery, intravenous administration, and direct administration by spraying onto the surface of an organ or application of a sheet or the like, and from the viewpoint of reducing the burden on the subject, intravenous administration is more preferred.
[0064] The dose (administration amount) of the immune disease therapeutic agent and liver disease therapeutic agent of the present invention may vary depending on the condition of the patient (body weight, age, symptoms, physical condition, etc.) and the dosage form of the immune disease therapeutic agent and liver disease therapeutic agent of the present invention, but from the viewpoint of exerting a sufficient therapeutic effect of the immune disease therapeutic agent and liver disease therapeutic agent, a larger amount tends to be preferable, while from the viewpoint of suppressing the occurrence of side effects, a smaller amount tends to be preferable. Usually, when administered to an adult, the number of cells is 1 x 10 3 ~1x10 12 Pieces / time, preferably 1x10 4 ~1x10 11 Pieces / time, preferably 1x10 5 ~1x10 10 Pieces / time, more preferably 5x10 6 ~1x10 9 The dosage per patient's weight is 1x10 to 5x10 10 Pieces / kg, preferably 1x10 2 ~5x10 9 pieces / kg, more preferably 1x10 3 ~5x10 8 / kg, more preferably 1x10 4 ~5x10 7 This dose may be administered multiple times as a single dose, or may be administered in multiple divided doses.
[0065] The immune disease therapeutic agent and liver disease therapeutic agent of the present invention may be administered together with one or more other drugs. Examples of the other drugs include any drug that can be used as a therapeutic agent for immune diseases, such as monoclonal antibodies such as abciximab, adalimumab, alemtuzumab, basiliximab, cetuximab, daclizumab, efalizumab, gemtuzumab, ibritumomab, infliximab, mepolizumab, OKT3, omalizumab, palivizumab, pexelizumab, rituximab, tositumomab, and trastuzumab. Examples of such cytokines include antibodies, fusion proteins such as alefacept, denileukin diftitox, and etanercept, soluble cytokine receptors such as anakinra, cytokines such as IFN-α, IFN-β, IFN-γ, IL-2, IL-11, erythropoietin, G-CSF, and GM-CSF, cyclosporine, azathioprine, mizoribine, tacrolimus hydrate, gusperimus hydrochloride, mycophenolate mofetil, and everolimus.Other drugs include any drug that can be used as a liver treatment drug, such as hepatitis B treatment drugs (lamivudine, adefovir, entecavir, tenofovir, etc.), interferon preparations (interferon α, interferon α-2b, interferon β, peginterferon α-2a, peginterferon α-2b, etc.), hepatitis C treatment drugs (ribavirin, telapirevir, simeprevir, vaniprevir, daclatasvir, asunaprevir, sofosbuvir, etc.), adrenal corticosteroids (prednisolone, methylprednisolone sodium succinate, etc.), anticoagulants (dried human antithrombin III concentrate, gabexate mesilate, thrombomodulin α, etc.), antidotes (edetate calcium disodium hydrate, glutathione, dimethycaprol, sodium thiosulfate hydrate, sugamadesc sodium, etc.), human serum albumin, liver extract, ursodeoxycholic acid, glycyrrhizic acid, azathioprine, bezafibrate, amino acids (glycine, L-cysteine, L-isoleucine, L-leucine, L-valine, L-threonine, L-serine, L-alanine, L-methionine, L-phenylalanine, L-tryptophan, L-lysine, L-histidine, L-arginine, and salts thereof, etc.), vitamins (tocopherol, flavin adenine dinucleotide, thiamine disulfide phosphate, pyridoxine, cyanocobalamin, and salts thereof, etc.), antibiotics (sulbactam sodium, cefoperazone sodium, meropenem hydrate, vancomycin hydrochloride, etc.).
[0066] The mesenchymal stem cells or mesenchymal stem cell-derived microparticles of the present invention can be used for various immune diseases and immune disorders, and specific diseases include immunodeficiency diseases such as graft-versus-host disease (GVHD), secondary immunodeficiency, primary immunodeficiency disease, B cell deficiency, T cell deficiency, combined B and T cell deficiency, NK cell deficiency, phagocyte deficiency, complement deficiency in the classical pathway, complement deficiency in the MBL pathway, complement deficiency in the alternative pathway, complement regulatory protein deficiency, and complement receptor deficiency, ataxia telangiectasia, Chediak-Higashi syndrome, chronic granulomatous disease, and pulmonary arterial disease. Allergic diseases and hypersensitivity diseases such as common variant immunodeficiency, DiGeorge syndrome, hyper-IgE syndrome, hyper-IgM syndrome, IgA deficiency, leukocyte adhesion deficiency, severe combined immunodeficiency, transient hypogammaglobulinemia, Wiskott-Aldrich syndrome, X-linked agammaglobulinemia (Bruton's disease), X-linked lymphoproliferative syndrome (Duncan syndrome), ZAP-70 deficiency, angioedema, hereditary angioedema, allergic rhinitis, food allergies, anaphylaxis, autoimmune diseases, drug hypersensitivity, and mastocytosis.
[0067] The mesenchymal stem cells or mesenchymal stem cell-derived microparticles of the present invention are effective in treating various liver diseases and liver disorders. Specific diseases include autoimmune hepatitis, fulminant hepatitis, chronic hepatitis, viral hepatitis, alcoholic hepatitis, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver (NAFL), hepatic fibrosis, liver cirrhosis, liver cancer, fatty liver, drug-induced allergic liver disease, hemochromatosis, hemosiderosis, Wilson's disease, primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), biliary atresia, liver abscess, chronic active hepatitis, and chronic persistent hepatitis. EXAMPLES
[0068] The present invention will be described in more detail below based on examples, but the present invention is not limited to these examples.
[0069] Example 1 [Preparation and culture of adipose-derived mesenchymal stem cells] Adipose-derived mesenchymal stem cells (Lonza Japan Co., Ltd., P#: PT-5006) were cultured at 37°C under low oxygen concentration (1%) for 72 hours to obtain low oxygen concentration cultured adipose tissue-derived mesenchymal stem cells. In addition, microparticles derived from adipose tissue-derived mesenchymal stem cells cultured under low oxygen concentration were obtained from the culture supernatant. The microRNA content of the microparticles was measured by microarray method, and it was revealed that the content of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634 was increased compared to the mesenchymal stem cell-derived microparticles cultured under normal oxygen concentration (atmospheric concentration). The results are shown in Figure 1.
[0070] Example 2 [Confirmation of therapeutic effects using autoimmune hepatitis model mice] Autoimmune hepatitis was induced in mice (BALB / cA, Japan CLEA) by administering concanavalin A (Sigma-Aldrich) at 20 mg / kg once. The mice with autoimmune hepatitis were injected with 1×10 adipose-derived mesenchymal stem cells (hASC-H) highly expressing miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634 obtained in Example 1, and normal adipose-derived mesenchymal stem cells (hASC). 6 Cells were administered intravenously once, and liver damage was evaluated. For comparison, animals not administered cells (Control) and healthy animals (Normal) were used. The results of measuring liver damage markers are shown in Figure 2 (AST) and Figure 3 (ALT). AST and ALT were measured using a transaminase measurement kit, respectively.
[0071] As shown in Figures 2 and 3, AST and ALT, which are markers of liver damage, increased by administration of concanavalin A (Control) compared to healthy mice (Normal). In contrast, the increase was significantly suppressed by administration of normal adipose-derived mesenchymal stem cells (hASCs), but the hepatitis-suppressing effect was further enhanced by administration of adipose-derived mesenchymal stem cells (hASC-H) that highly expressed miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p, and miR-634. From the above, it was revealed that adipose-derived mesenchymal stem cells with high expression of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634 have a significantly increased therapeutic effect against autoimmune hepatitis compared to normal adipose-derived mesenchymal stem cells.
[0072] Example 3 [Preparation of microparticles and investigation of their therapeutic effect on autoimmune hepatitis] The culture supernatant of the adipose-derived mesenchymal stem cells prepared in the same manner as above was collected, and the collected culture supernatant was filtered through a filter (0.22 μm, Merck Millipore), and then the microparticles were collected by centrifugation (35,000 rpm, 70 minutes, 4°C, BECKMAN Optima XE-90). The average particle size of the obtained microparticles was 145 ± 4.5 nm (mean ± standard error, n = 3).
[0073] The obtained adipose-derived mesenchymal stem cells (hASC-H) highly expressing miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634 and microparticles derived from normal adipose-derived mesenchymal stem cells (hASC), respectively, Exo(hASC-H) and Exo(hASC), were administered at 0.4μg each to mice with induced autoimmune hepatitis in the same manner as in Example 2, and liver damage was evaluated. Note that, for comparison, animals not administered with microparticles (Control) and healthy animals (Normal) were set up. The measurement results of liver damage markers are shown in Figure 4 (AST) and Figure 5 (ALT). Note that AST and ALT were measured using a transaminase measurement kit, respectively.
[0074] As shown in Figures 4 and 5, AST and ALT, which are markers of liver damage, increased by administration of concanavalin A (Control) compared to healthy mice (Normal). In contrast, the increase was significantly suppressed by administration of adipose-derived mesenchymal stem cell-derived microparticles Exo (hASC), but the suppressive effect was further enhanced by administration of adipose-derived mesenchymal stem cell-derived microparticles Exo (hASC-H) that highly expressed miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p, and miR-634. These results demonstrate that microparticles derived from adipose-derived mesenchymal stem cells highly expressing miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634 have a significantly increased therapeutic effect against autoimmune hepatitis compared to microparticles derived from normal adipose-derived mesenchymal stem cells.
[0075] These results suggest that adipose-derived mesenchymal stem cells with high expression of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634, and microparticles derived from adipose-derived mesenchymal stem cells with high expression of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634, have remarkable therapeutic effects against immune diseases and liver diseases. [Industrial Applicability]
[0076] The adipose-derived mesenchymal stem cells highly expressing miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634 and the microparticles derived from adipose-derived mesenchymal stem cells highly expressing miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634 of the present invention are preferably used as therapeutic agents exhibiting remarkable therapeutic effects against immune diseases and liver diseases.
Claims
1. A therapeutic agent for immune disease or liver disease, comprising adipose tissue-derived mesenchymal stem cells and / or a culture supernatant thereof containing microRNAs of miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634, wherein the adipose tissue-derived mesenchymal stem cells are obtained by culturing the adipose tissue-derived mesenchymal stem cells for 72 hours under conditions of 37°C and an oxygen concentration of 0.5% to 2.0%. a therapeutic agent for immune disease or liver disease, characterized in that the adipose tissue-derived mesenchymal stem cells are cultured in a medium containing 10% FBS under normal oxygen concentration (atmospheric concentration), and the microRNAs miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634 are highly expressed compared to when the medium is cultured in a DMEM medium containing 10% FBS under normal oxygen concentration (atmospheric concentration).
2. The therapeutic agent for immune disease or liver disease according to claim 1 , wherein the microRNA is contained in microparticles derived from adipose tissue-derived mesenchymal stem cells.
3. The therapeutic agent for immune diseases or liver diseases according to claim 2 , wherein the microparticles are exosomes.
4. A therapeutic agent for immune disease or liver disease containing microparticles derived from adipose tissue-derived mesenchymal stem cells, wherein the adipose tissue-derived mesenchymal stem cells are obtained by culturing for 72 hours under conditions of 37°C and an oxygen concentration of 0.5% to 2.0%, and the microparticles contain the microRNAs miR-210-3p, miR-6846-5p, miR-6757-3p, miR-23c, miR-195-5p, miR-129-2-3p, miR-129-1-3p and miR-634.
5. The therapeutic agent for immune disease or liver disease according to claim 1 , wherein the adipose tissue-derived mesenchymal stem cells are allogeneic to the subject.
Citation Information
Patent Citations
Mesenchymal stem cell originated from human adipose tissue and aimed at treatment of alzheimer's disease
JP2012157263A
Compositions for the prevention or treatment of neurological diseases, comprising mesenchymal stem cells or their culture medium.
JP2012508733A
Mesenchymal stem cell for treating hepatic disease
JP2016138092A
Mesenchymal Stem Cells Grown Under Hypoxic Conditions: Compositions, Methods and Uses Therefor
US20100330047A1
Low oxygen cultivation method for mesenchymal stem cells
WO2014200068A1
